In the subgroup of lung cancer patients, we observed the following differences that were significant or showed a strong trend when compared to baseline: sFLT (at RTduring, p = 0.05), PlGF (at RTduring and RTend, p = 0.01), VEGF-C (at RTduring and RTend, p < 0.001; at FU1, p = 0.04), VEGF-D (FU1, p < 0.001), INF-γ (FU1, p = 0.008), IL-8 (at RTend, p = 0.02; at FU1, p = 0.03; and at FU2, p = 0.03) and HGF (at FU1, p = 0.01). This evidence concerns the gene VEGFD and lung carcinoma.